NASDAQ:GNPX

Genprex Stock Forecast, Price & News

$3.28
-0.11 (-3.24 %)
(As of 06/21/2021 11:45 AM ET)
Add
Compare
Today's Range
$3.24
$3.33
50-Day Range
$3.11
$4.23
52-Week Range
$2.81
$7.72
Volume10,418 shs
Average Volume1.13 million shs
Market Capitalization$155.35 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.68
30 days | 90 days | 365 days | Advanced Chart
Receive GNPX News and Ratings via Email

Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter.


Genprex logo

About Genprex

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.18 out of 5 stars

Medical Sector

991st out of 2,100 stocks

Pharmaceutical Preparations Industry

482nd out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Genprex (NASDAQ:GNPX) Frequently Asked Questions

Is Genprex a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Genprex stock.
View analyst ratings for Genprex
or view top-rated stocks.

What stocks does MarketBeat like better than Genprex?

Wall Street analysts have given Genprex a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genprex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Genprex's next earnings date?

Genprex is scheduled to release its next quarterly earnings announcement on Thursday, June 24th 2021.
View our earnings forecast for Genprex
.

How were Genprex's earnings last quarter?

Genprex, Inc. (NASDAQ:GNPX) issued its quarterly earnings results on Sunday, May, 16th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.02.
View Genprex's earnings history
.

How has Genprex's stock price been impacted by COVID-19 (Coronavirus)?

Genprex's stock was trading at $2.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GNPX shares have increased by 40.1% and is now trading at $3.39.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GNPX?

1 analysts have issued twelve-month target prices for Genprex's shares. Their forecasts range from $7.00 to $7.00. On average, they expect Genprex's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 106.5% from the stock's current price.
View analysts' price targets for Genprex
or view top-rated stocks among Wall Street analysts.

Who are Genprex's key executives?

Genprex's management team includes the following people:
  • Mr. John Rodney Varner, Co, Founder, Pres, CEO, Sec. & Chairman (Age 64, Pay $750.94k)
  • Mr. Ryan M. Confer M.S., Chief Financial Officer (Age 39, Pay $522.53k)
  • Ms. Catherine M. Vaczy, Exec. VP, Gen. Counsel & Chief Strategy Officer (Age 60, Pay $646.02k)
  • Mr. Michael T. Redman, Exec. VP & COO (Age 66)
  • Ms. Kalyn Dabbs, Sr. Mang. of Communications & Marketing
  • Mr. Thomas C. Gallagher Esq., Sr. VP of Intellectual Property & Licensing
  • Dr. William E. Gannon Jr., Member of Clinical Advisory Board & VP of Regulatory Affairs
  • Dr. Jack A. Roth F.A.C.S., FACS, M.D., Chairman of Scientific & Medical Advisory Board

Who are some of Genprex's key competitors?

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), iBio (IBIO) and Advanced Micro Devices (AMD).

What is Genprex's stock symbol?

Genprex trades on the NASDAQ under the ticker symbol "GNPX."

Who are Genprex's major shareholders?

Genprex's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.22%), Geode Capital Management LLC (1.15%), Nuveen Asset Management LLC (0.85%), Northern Trust Corp (0.71%), Renaissance Technologies LLC (0.65%) and Millennium Management LLC (0.27%).
View institutional ownership trends for Genprex
.

Which institutional investors are selling Genprex stock?

GNPX stock was sold by a variety of institutional investors in the last quarter, including Altium Capital Management LP, JPMorgan Chase & Co., AQR Capital Management LLC, Bank of New York Mellon Corp, Morgan Stanley, Northern Trust Corp, and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for Genprex
or view top insider-selling stocks.

Which institutional investors are buying Genprex stock?

GNPX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nuveen Asset Management LLC, Millennium Management LLC, Geode Capital Management LLC, Royal Bank of Canada, Russell Investments Group Ltd., Iridian Asset Management LLC CT, and UBS Group AG.
View insider buying and selling activity for Genprex
or or view top insider-buying stocks.

How do I buy shares of Genprex?

Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genprex's stock price today?

One share of GNPX stock can currently be purchased for approximately $3.39.

How much money does Genprex make?

Genprex has a market capitalization of $160.56 million.

How many employees does Genprex have?

Genprex employs 12 workers across the globe.

What is Genprex's official website?

The official website for Genprex is www.genprex.com.

Where are Genprex's headquarters?

Genprex is headquartered at 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712.

How can I contact Genprex?

Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company can be reached via phone at 512-537-7997 or via email at [email protected]


This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.